Compare Neurocrine Biosciences Inc (NBIX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Prospect Capital Corporation — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Prospect Capital Corporation trades at $1.83 (market cap $974.22M). The key difference: Neurocrine Biosciences Inc is far larger — about 14.7× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Prospect Capital Corporation for 78 Days on average.
| NBIX | PSEC | |
|---|---|---|
Market Cap | $14.36B | $974.22M |
Volume | 1,237,180 | 5,779,996 |
Sector | Health | Financials |
52-Week High | $185.50 | $3.05 |
52-Week Low | $123.10 | $1.82 |
Typical Hold Time | 23 Days | 78 Days |
Enterprise Value | $14.37B | $2.73B |
Dividend Yield | — | 23.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
PSEC trades at $1.84, up 0.55% with bearish technical signals despite recent earnings beats. The company shows inconsistent revenue trends with 2025 revenue at -$407M and net income of -$470M, though 2026 projections indicate recovery. Dividend payments continue at $0.04 monthly, while analyst sentiment remains mixed with 25% buy ratings amid concerns about NAV erosion and portfolio contraction.
PSEC presents high risk with volatile financial performance and bearish technical indicators. The 18%+ dividend yield appears unsustainable given negative cash flow and declining portfolio value. While current price represents a significant discount to book value, ongoing NAV erosion and mixed analyst consensus suggest cautious approach for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
